MellmanI, CoukosG, and DranoffG: Cancer immunotherapy comes of age. Nature, 2011; 480:480–489.
3.
The Nobel Prize in Physiology or Medicine 2018 [Press Release]. Stockholm, Sweden: The Nobel Assembly at Karolinska Institutet, 2018.
4.
ParikhRB, MinEJ, WileytoEP, et al.: Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers. JAMA Oncol, 2021; 7:1843–1850.
5.
O'ConnorJM, FesseleKL, SteinerJ, et al.: Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials. JAMA Oncol, 2018; 4:e180798.
6.
HarringtonKJ, FerrisRL, BlumenscheinGJr, et al.: Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol, 2017; 18:1104–1115.
7.
PassaroA, SpitaleriG, GyawaliB, and de MarinisF: Immunotherapy in non–small-cell lung cancer patients with performance status 2: Clinical decision making with scant evidence. J Clin Oncol, 2019; 37:1863–1867.
8.
KanesvaranR, CordobaR, and MaggioreR: Immunotherapy in older adults with advanced cancers: Implications for clinical decision-making and future research. Am Soc Clin Oncol Educ Book, 2018; 38:400–414.
9.
LeBlancTW, TemelJS, and HelftPR: “How much time do I have?”: Communicating prognosis in the era of exceptional responders. J Clin Oncol 38:787–794, 2018.
10.
WheelerDA, TakebeN, HinoueT, et al.: Molecular features of cancers exhibiting exceptional responses to treatment. Cancer Cell, 2021; 39:38–53.
11.
BellmuntJ, de WitR, VaughnDJ, et al.: Pembrolizumab as second-line therapy for advance urothelial carcinoma. N Engl J Med, 2017; 376:1015–1026.
12.
PopatS, ArdizzoniA, CiuleanuT, et al.: Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status. Ann Oncol, 2017; 28:101 (abstr 1303PD).
13.
KhakiAR, LiA, DiamantopoulosLN, et al.: Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer, 2020; 126:1208–1216.
14.
SureshK, VoongKR, ShankarB, et al.: Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors. J Thorac Oncol, 2018; 13:1930–1939.
15.
GlischC, HagiwaraY, Gilbertson-White et al.: Immune checkpoint inhibitor use near the end of life is associated with poor performance status, lower hospice enrollment, and dying in the hospital. Am J Hosp Palliat Care, 2020; 37:179–184.
16.
GlischC, SaeidzadehS, SnydersT, et al.: Immune checkpoint inhibitor use near the end of life: A single-center retrospective study. J Palliat Med, 2020; 23:977–979.
17.
BangeEM, DoucetteA, GabrielPE, et al.: Opportunity costs of receiving palliative chemotherapy for metastatic pancreatic ductal adenocarcinoma. JCO Oncol Pract, 2020; 16:e678–e687.
18.
SedhomR, MacNabbL, SmithTJ, and YabroffKR: How palliative care teams can mitigate financial toxicity in cancer care. Support Care Cancer, 2021; 29:6175–6177.
19.
TemelJS, GainorJF, SullivanRJ, and GreerJA: Keeping expectations in check with immune checkpoint inhibitors. J Clin Oncol, 2018; 36:1654–1657.
20.
TemelJS, GreerJA, AdmaneS, et al.: Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: Results of a randomized study of early palliative care. J Clin Oncol, 2011; 29:2319–2326.
21.
BackAL, ArnoldRM, and QuillTE: Hope for the best, and prepare for the worst. Ann Intern Med, 2003; 138:439–443.
